Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.

Kriya is developing a portfolio of one-time gene therapies in ophthalmology, metabolic disease and neurology.

Kriya’s team of gene therapy pioneers and biopharma veterans is building a pipeline to address common diseases.

Sep 12, 2024 · KRIYA-586 is an investigational adeno-associated virus (AAV) gene therapy product engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor (IGF1R), a key …

Kriya’s gene therapy is designed for administration as a one-time, focal, peribulbar injection into fatty tissue around the eye, with a goal of achieving local antibody expression and minimizing systemic …

Careers Kriya is Changing the Future of Gene Therapy We have an ambitious set of goals, but our confidence – and our inspiration – stems from our people. From California to North Carolina, our …

Kriya is developing KRIYA 839, a potential one-time gene therapy for type 1 diabetes expressing insulin and glucokinase, designed to be delivered intramuscularly with the objective of driving durable …

Jul 26, 2023 · Since its founding in October 2019, Kriya has raised over $600 million in committed capital—and with this financing, Kriya’s cash runway is anticipated to run into late 2026. Kriya is …

Jan 8, 2024 · – Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, …

Erik Hughes is the Senior Vice President of Technical Development at Kriya. Erik joined Kriya from Biogen where he held various roles including Director of Global Process Sciences and Director of …